Evidence-Based Treatment of Thalassemia Major

Evidence-Based Hematology

Volumn , Issue , 2009, Pages 251-259

  Odame, Issac ^a   Rund, Deborah ^b   Lottenberg, Richard ^c  

^a HOSPITAL FOR SICK CHILDREN   (Canada)

^b HEBREW UNIVERSITY OF JERUSALEM   (Israel)

^c UNIVERSITY OF FLORIDA COLLEGE OF MEDICINE   (United States)

Author keywords

Clinical trials on desferrioxamine (DFO); Cord blood transplantation; Desferrioxamine and deferiprone combinations; Evidence based findings on treatment of transfusion dependent thalassemia major; Grading of evidence and recommendations; Risks of splenectomy; Splenectomy in transfused patients?; Thalassemia major; Transplants from HLA identical related donors; Transplants from HLA unrelated donors

Indexed keywords

EID: 84891040211     PISSN: None     EISSN: None     Source Type: Book    
DOI: 10.1002/9781444300857.ch31     Document Type: Chapter

References (55)

1. Guyatt G, Gutterman D, Baumann MH, Addrizzo-Harris D, Hylek EM, Phillips B, Raskob G, Lewis SZ, Schunemann H. Grading strength of recommendations and quality of evidence in clinical guidelines: report from an American College of Chest Physicians Task Force. Chest. 2006;129(1):174-81.
2. Piomelli S. The management of patients with Cooley's anemia: transfusions and splenectomy. Semin Hematol. 1995;32(4):262-68.
3. Propper RD, Button LN, Nathan DG. New approaches to the transfusion management of thalassemia. Blood. 1980;55(1):55-60.
4. Masera G, Terzoli S, Avanzini A, et al. Evaluation of the supertransfusion regimen in homozygous beta-thalassaemia children. Br J Haematol. 1982;52(1):111-13.
5. Gabutti V, Piga A, Nicola P, et al. Haemoglobin levels and blood requirement in thalassaemia. Arch Dis Child. 1982;57(2):156-58.
6. Rebulla P, Modell B. Transfusion requirements and effects in patients with thalassaemia major. Cooleycare Programme. Lancet. 1991;337(8736):277-80.
7. Cazzola M, De Stefano P, Ponchio L, et al. Relationship between transfusion regimen and suppression of erythropoiesis in beta-thalassaemia major. Br J Haematol. 1995;89(3):473-78.
8. Borgna-Pignatti C, Cappellini MD, De Stefano P, et al. Cardiac morbidity and mortality in deferoxamine- or deferiprone-treated patients with thalassemia major. Blood. 2006;107(9):3733-37.
9. Roberts DJ, Rees D, Howard J. Desferrioxamine mesylate for managing transfusional iron overload in people with transfusion-dependent thalassaemia. Cochrane Database Syst Rev. 2005;4:CD004450.
10. Neufeld EJ. Oral chelators deferasirox and deferiprone for transfusional iron overload in thalassemia major: new data, new questions. Blood. 2006;107(9):3436-41.
11. Hershko CM, Link GM, Konijn AM, et al. Iron chelation therapy. Curr Hematol Rep. 2005;4(2):110-16.
12. Wolfe L, Olivieri N, Sallan D, et al. Prevention of cardiac disease by subcutaneous deferoxamine in patients with thalassemia major. N Engl J Med. 1985;312(25):1600-603.
13. Ceci A, Baiardi P, Felisi M, et al. The safety and effectiveness of deferiprone in a large-scale, 3-year study in Italian patients. Br J Haematol. 2002;118(1):330-36.
14. VictorHoffbrand A. Deferiprone therapy for transfusional iron overload. Best Pract Res Clin Haematol. 2005;18(2):299-317.
15. Nisbet-Brown E, Olivieri NF, Giardina PJ, et al. Effectiveness and safety of ICL670 in iron-loaded patients with thalassaemia: a randomised, double-blind, placebo-controlled, dose-escalation trial. Lancet. 2003;361(9369):1597-602.
16. Piga A, Galanello R, Forni GL, et al. Randomized phase II trial of deferasirox (Exjade, ICL670), a once-daily, orally-administered iron chelator, in comparison to deferoxamine in thalassemia patients with transfusional iron overload. Haematologica. 2006;91(7):873-80.
17. Cappellini MD, Cohen A, Piga A, et al. A phase 3 study of deferasirox (ICL670), a once-daily oral iron chelator, in patients with betathalassemia. Blood. 2006;107(9):3455-62.
18. Giardina PJ, Grady RW. Chelation therapy in beta-thalassemia: an optimistic update. Semin Hematol. 2001;38(4):360-66.
19. Link G, Konijn AM, Breuer W, et al. Exploring the "iron shuttle" hypothesis in chelation therapy: effects of combined deferoxamine and deferiprone treatment in hypertransfused rats with labeled iron stores and in iron-loaded rat heart cells in culture. J Lab ClinMed. 2001;138(2):130-38.
20. Pennell DJ, Berdoukas V, Karagiorga M, et al. Randomized controlled trial of deferiprone or deferoxamine in beta-thalassemia major patients with asymptomatic myocardial siderosis. Blood. 2006;107(9): 3738-44.
21. Wonke B, Wright C, Hoffbrand AV. Combined therapy with deferiprone and desferrioxamine. Br J Haematol. 1998;103(2):361-64.
22. Mourad FH, Hoffbrand AV, Sheikh-Taha M, et al. Comparison between desferrioxamine and combined therapy with desferrioxamine and deferiprone in iron overloaded thalassaemia patients. Br J Haematol. 2003;121(1):187-89.
23. Alymara V, Bourantas D, Chaidos A, et al. Effectiveness and safety of combined iron-chelation therapy with deferoxamine and deferiprone. Hematol J. 2004;5(6):475-79.
24. Origa R, Bina P, Agus A, Crobu G, et al. Combined therapy with deferiprone and desferrioxamine in thalassemia major. Haematologica. 2005;90(10):1309-14.
25. Galanello R, Kattamis A, Piga A, et al. A prospective randomized controlled trial on the safety and efficacy of alternating deferoxamine and deferiprone in the treatment of iron overload in patientswith thalassemia major. Haematologica 2005;91(9):1241-43.
26. Kattamis A, Ladis V, Berdousi H, et al. Iron chelation treatment with combined therapywith deferiprone and deferioxamine: a 12-month trial. Blood Cells Mol Dis. 2006;36(1):21-25.
27. Modell B. Total management of thalassaemia major. Arch Dis Child. 1977;52:489-500.
28. Cohen A, Markenson AL, Schwartz E. Transfusion requirements and splenectomy in thalassemia major. J Pediatr. 1980;97(1):100-102.
29. Graziano JH, Piomelli S, Hilgartner M, et al. Chelation therapy in ß- thalassemia major: the role of splenectomy in achieving iron balance. J Pediatr. 1981;99(5):695-99.
30. Cohen A, Gayer R, Mizanin J. Long-termeffect of splenectomy on transfusion requirements in thalassemia major. Am J Hematol. 1989;30:254-56.
31. Bisharat N, Omari H, Lavi I, et al. Risk of infection and death among post-splenectomy patients. J Infect. 2001;43:182-86.
32. Davies JM, Barnes R, Milligan D. Update on guidelines for the prevention and treatment of infection in patients with absent or dysfunctional spleen. Clin Med. 2002;2(5):440-43.
33. Cappelini MD, Grespi E, Cassinerio E, et al. Coagulation and splenectomy: an overview. Ann N Y Acad Sci. 2005;1054:317-24.
34. Lucarelli G, Galimberti M, Polchi P, et al. Bone marrow transplantation in patients with thalassemia. N Engl J Med. 1990;322:417-21.
35. Lucarelli G, Galimberti M, Polchi P, et al. Marrow transplantation in patients with thalassemia responsive to iron chelation. N Engl J Med. 1993;329:840-44.
36. Galimberti M, Polchi P, Angelucci E, et al. Bone marrow transplantation in thalassemia: the experience of Pesaro. Bone Marrow Transplant. 1997;19:45-47.
37. Walters MC, Sullivan KM, O'Reilly RJ, et al. Bone marrow transplant for thalassemia: the USA experience. Am J Pediatr Oncol. 1994;16: 11-17.
38. Lawson SE, Roberts IAG, Amrolia P, et al. Bone marrow transplantation for ß-thalassaemia major: the UK experience in two pediatric centers. Br J Haematol. 2003;120:289-95.
39. Sodani P, Gaziev D, Polchi P, et al. New approach to bone marrow transplantation inpatientswith class 3 thalassemia aged younger than 17 years. Blood. 2004;104:1201-3.
40. Graziev J, Sodani P, Polchi P, et al. Bone marrowtransplantation in adults with thalassemia. Treatment and long-termfollow-up. Ann NY Acad Sci. 2005;1054:196-205.
41. La Nasa G, Giardini C, Argiolu F, et al. Unrelated donor bone marrow transplantation for thalassemia: the effect of extended haplotypes. Blood. 2002;99:4350-56.
42. Hongeng S, Pakakasama S, Chuansumrit A, et al. Outcomes of transplantation with related- and unrelated-donor stem cells in children with severe thalassemia. Biol Blood Marrow Transplant. 2006;12:683-87.
43. Locatelli F, Rocha V, Reed W, et al. Related umbilical cord blood transplantation in patients with thalassemia and sickle cell disease. Blood. 2003;101:2137-43.
44. Locatelli F, De Stefano P. Innovative approaches to hemopoietic stem cell transplantation for patients with thalassemia. Haematologica. 2005;90(12):1592-94.
45. Steinberg MH, Rogers GP. Pharmacological modulation of fetal hemoglobin. Medicine. 2001;80:328-44.
46. Atweh GF, Loukopoulos D. Pharmacological induction of fetal hemoglobin in sickle cell disease and ß-thalassemia. Semin Hematol. 2001;38:367-73.
47. DeSimone J, Heller P, Hall L, et al. 5-azacytidine stimulates fetal hemoglobin synthesis in anemic baboons. Proc Natl Acad Sci U S A. 1982;79:4428-31.
48. Koshy M, Dorn L, Bresller L, et al. 2-Deoxy 5-azacytidine and fetal hemoglobin induction in sickle cell anemia. Blood. 2000;96:2379-84.
49. Charache S, Terrin ML, Moore RD, et al. Effect of hydroxyurea on the frequency of painful crisis in sickle cell anemia. Investigators of theMulticenter Study of Hydroxyurea in Sickle Cell Anemia. N Engl J Med. 1995;332:1317-22.
50. Alebouyeh M, Moussavi F, Haddad-Deylami H, et al. Hydroxyurea in the treatment of major ß-thalassemia and importance of genetic screening. Ann Hematol. 2004;83:430-33.
51. Yavarian M, Karimi M, Bakker E, et al. Response to hydroxyurea treatment in Iranian transfusion-dependent ß-thalassemia patients. Haematologica. 2004;89(10):1172-78.
52. Fucharoen S, Siritanaratkul N, Winichagoon P, et al. Hydroxyurea increasesHemoglobin F levels and improves effectiveness of erythropoiesis in ß-thalassemia/hemoglobin E disease. Blood. 1996;87(3):887-92.
53. Singer S, Kuypers F, Olivieri N, et al. Fetal haemoglobin augmentation in E/ß0 thalassaemia: clinical and haematological outcome. Br J Haematol. 2005;131:378-88.
54. Perrine SP, Castaneda SA, Boosalis MS, et al. Induction of fetal globin in ß-thalassemia: cellular obstacles and molecular progress. Ann NY Acad Sci. 2005;1054:257-65.
55. Fathallah H, Sutton M, Atweh GF. Pharmacological induction of fetal hemoglobin: why havent we been more successful in thalassemia?. Ann NY Acad Sci. 2005;1054:228-37.